Guinea-BissauTuberculosis profile
Population  2016 1.8 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.4 (0.8–2.1) 76 (44–116)
Mortality (HIV+TB only) 1.2 (0.73–1.8) 66 (40–98)
Incidence  (includes HIV+TB) 6.8 (4.4–9.7) 374 (242–534)
Incidence (HIV+TB only) 2.2 (1.4–3.2) 120 (75–175)
Incidence (MDR/RR-TB)** 0.2 (0.017–0.39) 11 (0.93–21)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.42 (0.26–0.59) 2.2 (1.3–3) 2.6 (1.6–3.6)
Males 0.48 (0.29–0.67) 3.7 (2.3–5.2) 4.2 (2.6–5.9)
Total 0.9 (0.55–1.3) 5.9 (3.6–8.2) 6.8 (4.4–9.7)
TB case notifications, 2016  
Total cases notified 2 247
Total new and relapse 2 226
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 70%
          - % pulmonary 96%
          - % bacteriologically confirmed among pulmonary 83%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 33% (23–51)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.39 (0.21–0.6)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 506 32%
          - on antiretroviral therapy 247 49%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  67
(12–120)
Estimated % of TB cases with MDR/RR-TB 2.6% (0.1–5.1) 18% (0.1–36)  
% notified tested for rifampicin resistance      
MDR/RR-TB cases tested for resistance to second-line drugs    
Laboratory-confirmed cases MDR/RR-TB: 37, XDR-TB:
Patients started on treatment **** MDR/RR-TB: 36, XDR-TB:
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 79% 2 147
Previously treated cases, excluding relapse, registered in 2015 100% 5
HIV-positive TB cases registered in 2015 68% 422
MDR/RR-TB cases started on second-line treatment in 2014 40% 15
XDR-TB cases started on second-line treatment in 2014    
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
4.5% (4.1–4.9)
TB financing, 2017  
National TB budget (US$ millions) 3.2
Funding source: 3% domestic, 71% international, 26% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-17 Data: www.who.int/tb/data